![]() | |
Clinical data | |
---|---|
Other names | trans-4-hydroxycrotonic acid |
ATC code |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider |
|
UNII | |
ChEMBL | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C4H6O3 |
Molar mass | 102.089 g·mol−1 |
3D model (JSmol) | |
| |
| |
![]() ![]() |
trans-4-Hydroxycrotonic acid (T-HCA), also known as γ-hydroxycrotonic acid (GHC), is an agent used in scientific research to study the GHB receptor.[1] It is an analogueofγ-hydroxybutyric acid (GHB), as well as an active metabolite of GHB.[2][3][4] Similarly to GHB, T-HCA has been found to be endogenous to the rat central nervous system, and as a metabolite of GHB, is almost certain to be endogenous to humans as well.[3][5] T-HCA binds to the high-affinity GHB receptor with 4-fold greater affinity than GHB itself,[6] where it acts as an agonist,[1][7] but does not bind to the low-affinity GHB binding site, the GABAB receptor.[3][8] Because of this, T-HCA does not produce sedation. T-HCA has been shown to cause receptor activation-evoked increases in extracellular glutamate concentrations, notably in the hippocampus.[8]
| |||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Amino acid-derived |
| ||||||||||||||||||||||
Lipid-derived |
| ||||||||||||||||||||||
Nucleobase-derived |
| ||||||||||||||||||||||
Vitamin-derived |
| ||||||||||||||||||||||
Miscellaneous |
|
| |||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
Receptor (ligands) |
| ||||||||||
Transporter (blockers) |
| ||||||||||
Enzyme (inhibitors) |
| ||||||||||
|
![]() | This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it. |